The DOI matches its Crossref record.
A high proportion of founder BRCA1 mutations in Polish breast cancer families
Open accessAbstract
Three mutations in BRCA1 (5382insC, C61G and 4153delA) are common in Poland and account for the majority of mutations identified to date in Polish breast and breast–ovarian cancer families. It is not known, however, to what extent these 3 founder mutations account for all of the BRCA mutations distributed throughout the country. This question has important implications for health policy and the design of epidemiologic studies. To establish the relative contributions of founder and nonfounder BRCA mutations, we established the entire spectrum of BRCA1 and BRCA2 mutations in a large set of breast–ovarian cancer families with origins in all regions of Poland. We sequenced the entire coding regions of the BRCA1 and BRCA2 genes in 100 Polish families with 3 or more cases of breast cancer and in 100 families with cases of both breast and ovarian cancer. A mutation in BRCA1 or BRCA2 was detected in 66% of breast cancer families and in 63% of breast–ovarian cancer families. Of 129 mutations, 122 (94.6%) were in BRCA1 and 7 (5.4%) were in BRCA2. Of the 122 families with BRCA1 mutations, 119 (97.5%) had a recurrent mutation (i.e., one that was seen in at least 2 families). In particular, 111 families (91.0%) carried one of the 3 common founder mutations. The mutation spectrum was not different between families with and without ovarian cancer. These findings suggest that a rapid and inexpensive assay directed at identifying the 3 common founder mutations will have a sensitivity of 86% compared to a much more costly and labor‐intensive full‐sequence analysis of both genes. This rapid test will facilitate large‐scale national epidemiologic and clinical studies of hereditary breast cancer, potentially including studies of chemoprevention. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
Self-citationBreast cancer risk associated with BRCA1 and BRCA2 in diverse populations
Fackenthal, J. D., & Olopade, O. I. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2054 · Cited by 488
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 340
Self-citationPathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., Jakubowicz, J., Cybulski, C., Wisniowski, R., Godlewski, D., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3100-x · Cited by 269
Self-citationCybulski, C., Wokołorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., Masojć, B., Dębniak, T., Górski, B., Blecharz, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0778 · Cited by 254
Self-citation
Metadata
- Authors
- Górski, B., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., Grzybowska, E., Mackiewicz, A., Stawicka, M., Bębenek, M., Sorokin, D., Fiszer‐Maliszewska, Ł., Haus, O., Janiszewska, H., Niepsuj, S., Góźdź, S., Zaremba, L., Posmyk, M., Płużańska, M., Kilar, E., Czudowska, D., Waśko, B., Miturski, R., Kowalczyk, J. R., Urbański, K., Szwiec, M., Koc, J., Dębniak, B., Rozmiarek, A., Dębniak, T., Cybulski, C., Kowalska, E., Tołoczko‐Grabarek, A., Zajączek, S., Menkiszak, J., Mędrek, K., Masojć, B., Mierzejewski, M., Narod, S. A., & Lubiński, J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-03-15
- Volume
- 110
- Issue
- 5
- Pages
- 683-686
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2045667568
- Cited by
- 194
- References
- 0
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.